StockNews.AI
RVMD
StockNews.AI
181 days

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

1. Revolution Medicines to announce Q4 and full year 2024 results on February 26. 2. A webcast will detail fourth-quarter results and corporate updates at 4:30 PM ET. 3. Company focuses on RAS(ON) inhibitors for RAS-addicted cancers in clinical development. 4. Key drugs include daraxonrasib, elironrasib, and zoldonrasib for specific RAS mutations. 5. Pipeline includes inhibitors targeting additional RAS mutations like G12V and Q61H.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and positive pipeline developments could attract investors, similar to prior earnings announcements that led to price gains following favorable updates.

How important is it?

Earnings reports and clinical updates significantly affect investor sentiment and price actions, particularly in biotech sectors focused on innovation in cancer therapies.

Why Short Term?

Immediate price impact likely due to upcoming earnings; past earnings reports have historically influenced short-term price movement.

Related Companies

RVMDRMC-6236RMC-6291RMC-9805
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days. About Revolution Medicines, Inc.Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn. Revolution Medicines Media & Investor Contact:media@revmed.cominvestors@revmed.com

Related News